Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oncoimmunology. 2021 Nov 25;10(1):2008111. doi: 10.1080/2162402X.2021.2008111. eCollection 2021.
Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.
白细胞介素-1（IL-1）是一种与肿瘤侵袭和转移相关的炎症细胞因子。我们最近发现，黑色素瘤中的基线 IL-1 通过创建免疫抑制性肿瘤微环境来促进对免疫疗法的抵抗，而对 CD40 激动剂的反应产生的 IL-1 也诱导了对治疗的抵抗。在这里，我们讨论了肿瘤中天然存在的和免疫疗法诱导的 IL-1 如何引起免疫抑制和对免疫疗法的抵抗，并讨论了靶向 IL-1 途径以增强免疫疗法的疗效。
